陈鸣声
教授,硕士生导师
电子邮箱:cms@njmu.edu.cn
主要研究方向:卫生经济与政策、卫生服务研究、卫生技术评估
个人简介:
陈鸣声,南京医科大学医政学院副院长,博士,教授,硕士生导师。江苏省社科优青、江苏省高校“青蓝工程”优秀青年骨干教师、南京医科大学优秀中青年学科(学术)带头人。主持美国中华医学会CMB-OC项目1项;主持国家自然科学基金项目2项,以第一和通讯作者发表SCI/SSCI论文16篇,出版专著1部。受聘Springer Nature出版集团BMC Health Services Research期刊副主编(Associate Editor),SSCI期刊Social Indicators Research特邀主编(Lead Guest Editor)。现任中华预防医学会卫生事业管理分会青年委员,中国医药卫生管理大学联盟青年委员会执委,江苏省卫生经济学会基层卫生经济管理专委会副主任委员。2008-2009年国家卫生发展研究中心进修,2014年澳大利亚昆士兰科技大学健康学院访问学者。
1.《多元共同决策视角下慢性病共病管理模式构建、评价与优化:基于社区干预试验》,国家自然科学基金面上项目(项目编号72174093),2022/01-2025/12
2. Establishing a cost-effectiveness threshold for health technology assessments to promote optimal and transparent health-care funding decisions in China, CMB OC (Grant NO. 19-346), 2020/01-2022/12
3.《基于安德森卫生服务利用模型的社区慢病个性化健康服务模式构建与效果评价》,国家自然科学基金面上项目(项目编号71874086),2019/01-2022/12
4.《卫生筹资再分配视角下全民健康覆盖的筹资机制实证研究与策略构建》,国家自然科学基金青年科学基金项目(项目编号71503137),2016/01-2018/12
5.《苏北农村地区基层卫生人才队伍建设策略研究》,江苏省社科应用研究(人才发展)课题(项目编号14SRB-27),2014/05-2014/12
代表性研究成果:
1. Mingsheng Chen, Guoliang Zhou, Lei Si*, Ten years of progress towards universal health coverage: has China achieved equitable healthcare financing?. BMJ Global Health, 2020, 5:e003570.
2. Zhonghua Wang, Xiangjun Li, Mingsheng Chen (Corresponding author), Socioeconomic Factors and Inequality in the Prevalence and Treatment of Diabetes among Middle-Aged and Elderly Adults in China. Journal of Diabetes Research, 2018: 1-12
3. Mingsheng Chen, Andrew J Palmer, Lei Si*, Improving equity in health care financing in China during the progression towards Universal Health Coverage.BMC Health Services Research, 2017, 17(1):852
4. Mingsheng Chen, Lei Si*, Tania M Winzenberg, JieruoGu, Qicheng Jiang, Andrew J Palmer, Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence. Patient Prefer Adherence, 2016, 10(1):415-423
5. Mingsheng Chen, Lijie Wang, Wen Chen*, Luying Zhang, Hongli Jiang, Wenhui Mao, Does economic incentive matter rational use of medicine? China’s experience from Essential Medicines Program. PharmacoEconomics, 2014, 32(3):245-255